Patent · US Active

Antibodies against LIF and uses thereof

US11390670B2 · kind B2 · utility

1Cited by

14References

16Claims

0Family size

Assignees

MedImmune Limited · US
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGIC · ES
FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I · ES

Inventors

Joan SEOANE SUAREZ · Barcelona, ES
Judit ANIDO FOLGUEIRA · Barcelona, ES
Johan Fransson · San Diego, US
Jean-Philippe Julien · Toronto, CA
Swetha RAMAN · Toronto, CA

Key dates

Filing date	Dec 18, 2017
Grant date	Jul 19, 2022
Priority date	—
Expiry date	Nov 6, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.